血管活性肠:一种神经,在帕金森病中起着重要的作用
Wenhui Fan1, Ke Li1, Ruohua Wang1
1Central Laboratory, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan Province, China.
Current neuropharmacology
|May 12, 2025
概括
血管活性肠 (VIP) 通过保护神经细胞来治疗帕金森病 (PD) 是有前途的. 对VIP作为脑肠的进一步研究可能会导致PD的新治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 胃肠病学 胃肠病学
背景情况:
- 帕金森病 (PD) 涉及α-synuclein聚合和神经退行,目前的治疗只提供症状管理.
- 血管活性肠 (VIP) 是一种神经递质,在神经系统中具有广泛的影响.
- VIP表现出神经保护性质,包括抗炎,抗氧化和抗丧功能.
研究的目的:
- 审查目前关于用于帕金森病 (PD) 治疗的血管活性肠 (VIP) 的研究.
- 探索VIP的潜力,作为一种治疗药物,在PD中准大脑-肠轴.
- 确定PD治疗中VIP的未来研究方向.
主要方法:
- 对调查VIP在神经保护和PD中的作用的研究文献综述.
- 对VIP对神经元和质细胞的生物学影响的分析.
- 在PD的背景下,检查VIP与大脑-肠轴的相互作用.
主要成果:
- VIP表现出与PD病理学相关的显著神经保护作用.
- VIP调节免疫和质细胞,有助于神经细胞的修复.
- 有证据表明,VIP作为PD治疗干预的潜力.
结论:
- 血管活性肠 (VIP) 为帕金森病提供了一个有前途的治疗途径.
- 针对大脑-肠轴的VIP保证了PD治疗的进一步调查.
- 未来的研究应该集中在治疗PD的VIP的临床应用上.
相关概念视频
Parkinson's Disease: Treatment
154
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
154
Parkinson's Disease: Overview
319
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
319
Neural Regulation
39.0K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.0K
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
176
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
176
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
194
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
194
Indirect-Acting Cholinergic Agonists: Pharmacological Actions
562
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
562


